Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
Year: 2010
Type: article
Abstract: Multiple myeloma (MM) is a malignant hematological neoplasia of plasma cells. The clinical manifestations of MM are heterogeneous and include monoclonal immunoglobulin production, hypogammaglobulinemia, impaired hematopoiesis, osteolytic bone disease, hypercalcemia, and renal dysfunction. Recently, novel agents such as thalidomide, lenalidomide, and bortezomib were introduced for the treatment of MM; treatment with these agents can effectively control both relapsed and newly diagnosed diseases and thereby improve survival. Patients with MM show heterogeneous outcomes, which range from a relatively indolent course with a lengthy survival period to a more aggressive disease course with dismal prognosis. Therefore, identification of these subgroups of patients has great clinical significance. Several factors related
Source: The Korean Journal of Hematology
Author: Je-Jung Lee
Institution: Chonnam National University Hwasun Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2016211497
